Breaking
•EU COUNCIL: TO INCREASE, FROM 2026 TO 2030, FREE CARBON ALLOWANCES FOR SECTORS UNDER HEAT AND FUEL BENCHMARKS OF EU’S EMISSIONS TRADING SYSTEM - CGTN•Russian court jails rights lawyer for 12 years on treason charge•New Clarity About Amanda Seyfried’s ‘You Can See Everything’ Awards Eligibility, Actress Is Excited to Campaign: “They’re Going to Let Me Loose” (Exclusive)•Sukhbir Badal likely to meet Amit Shah on November 13, SAD-BJP alliance may be announced this month•Scandal-hit Nvidia CEO Jensen Huang quits, plunging AI chipmaking giant into turmoil•Gut and urogenital microbiomes influence menopausal hormone therapy outcomes•[Viewpoint] Ambient scribes as narrative technologies•[The Lancet Commissions] A Lancet Commission on the Health and Poverty Alleviation Initiative in China•[Articles] Empirical tuberculosis treatment in infants living with HIV hospitalised with severe pneumonia in Africa (EMPIRICAL): a multicentre, randomised, open-label, 2 × 2 factorial, controlled superiority trial•[Articles] First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial•[Articles] 14-day versus 28-day trifluridine–tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan•[Department of Error] Department of Error•[Department of Error] Department of Error•[Correspondence] WHO's operational role in emergencies: a view from Gaza•[Correspondence] The Perth Declaration to eliminate rheumatic fever and rheumatic heart disease•[Perspectives] Silencing: a medical intern in the Gaza Strip•[Perspectives] Critical thinking about assisted dying•[Perspectives] Lalitha Regi and Regi George: strengthening community health•[World Report] Access to medicines: innovations not reaching those in need•[World Report] WHO's next Director-General•EU COUNCIL: TO INCREASE, FROM 2026 TO 2030, FREE CARBON ALLOWANCES FOR SECTORS UNDER HEAT AND FUEL BENCHMARKS OF EU’S EMISSIONS TRADING SYSTEM - CGTN•Russian court jails rights lawyer for 12 years on treason charge•New Clarity About Amanda Seyfried’s ‘You Can See Everything’ Awards Eligibility, Actress Is Excited to Campaign: “They’re Going to Let Me Loose” (Exclusive)•Sukhbir Badal likely to meet Amit Shah on November 13, SAD-BJP alliance may be announced this month•Scandal-hit Nvidia CEO Jensen Huang quits, plunging AI chipmaking giant into turmoil•Gut and urogenital microbiomes influence menopausal hormone therapy outcomes•[Viewpoint] Ambient scribes as narrative technologies•[The Lancet Commissions] A Lancet Commission on the Health and Poverty Alleviation Initiative in China•[Articles] Empirical tuberculosis treatment in infants living with HIV hospitalised with severe pneumonia in Africa (EMPIRICAL): a multicentre, randomised, open-label, 2 × 2 factorial, controlled superiority trial•[Articles] First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial•[Articles] 14-day versus 28-day trifluridine–tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan•[Department of Error] Department of Error•[Department of Error] Department of Error•[Correspondence] WHO's operational role in emergencies: a view from Gaza•[Correspondence] The Perth Declaration to eliminate rheumatic fever and rheumatic heart disease•[Perspectives] Silencing: a medical intern in the Gaza Strip•[Perspectives] Critical thinking about assisted dying•[Perspectives] Lalitha Regi and Regi George: strengthening community health•[World Report] Access to medicines: innovations not reaching those in need•[World Report] WHO's next Director-General
TheNewsPulse.pro
Home/business/community/government
business

Georgia-Pacific to invest $20 million in its Paragould facility - Talk Business & Politics

Confidence80·developingImportance85NP-EVT-20261112-B3B09DB

Georgia-Pacific to invest $20 million in its Paragould facility    Talk Business & Politics

Read the original at the primary source
Georgia-Pacific to invest $20 million in its Paragould facility - Talk Business & Politics
11/12/2026, 11:00:01 PM
Also on the network: airlinesairports · farmerspulse · foodpulse · indias · naturepulse · travelerpulse

Discussion

ChatsPulse · 0 threads

No discussion yet. Sign in and start the first thread —